Related Experiment Video
Updated: Aug 18, 2025
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
Oral Chinese patent medicines for acute myocardial infarction after percutaneous coronary intervention: A protocol
Wei Zhao1, Fan-Jie Xiong1, Shu-Gui Feng2
1Xindu Hospital of Traditional Chinese Medicine Affiliated to Chengdu Medical College, Chengdu, China.
Insights
This network meta-analysis compares oral Chinese patent medicines for treating acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). It aims to identify the most effective and safe treatment options for AMI patients post-PCI.
Area of Science:
- Cardiology
- Pharmacology
- Evidence-Based Medicine
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
- Percutaneous coronary intervention (PCI) is a primary reperfusion strategy, but post-PCI treatment remains challenging.
- Oral Chinese patent medicines show potential for treating AMI post-PCI, but optimal choices are debated.
Purpose of the Study:
- To conduct a network meta-analysis comparing the efficacy and safety of various oral Chinese patent medicines for treating AMI after PCI.
- To provide evidence-based guidance on preferred oral Chinese patent medicines for AMI patients undergoing PCI.
Main Methods:
- Comprehensive literature search across multiple databases (PubMed, Embase, Web of Science, SinoMed, Wanfang, VIP, Cochrane) in Chinese and English until November 2022.
- Study selection and quality assessment following PRISMA guidelines and Cochrane Collaboration's tool.
- Pairwise and network meta-analysis using WinBUGS and STATA, including sensitivity, subgroup, and bias analyses.
Main Results:
- The analysis will compare multiple oral Chinese patent medicines for their effectiveness and safety in treating AMI post-PCI.
- Results will identify potential superior treatments among the evaluated Chinese patent medicines.
- Statistical analyses will assess efficacy endpoints and safety profiles.
Conclusions:
- This network meta-analysis will elucidate the comparative efficacy and safety of oral Chinese patent medicines for AMI post-PCI.
- Findings will inform clinical decision-making regarding the use of these therapies.
- The study aims to optimize treatment strategies for AMI patients undergoing PCI.
Background:
Acute myocardial infarction (AMI) is a serious and fatal heart disease with one of the highest mortality rates in the world. In some countries, percutaneous coronary intervention (PCI) is the preferred reperfusion strategy after AMI, but it cannot achieve safe and effective treatment of AMI after PCI remains a challenging clinical problem. The potential of oral Chinese patent medicines to treat AMI after PCI has been demonstrated, but which type of oral Chinese patent medicines may be preferred remains controversial. The aim of this network meta-analysis was to investigate the efficacy and safety of multiple oral Chinese patent medicines in the treatment of AMI after PCI.
Methods:
We will conduct a literature search from China National Knowledge Infrastructure, formerly Chinese Biomedical Database (SinoMed), Wanfang Data, Chongqing VIP, PubMed, Embase, Web of Science and Cochrane Library (The Cochrane Database of Systematic Reviews) from their inception until to November 1, 2022, with language restricted to Chinese and English. Then, the study selection process will follow the Preferred Reporting Items for Meta-Analyses guideline, and the quality assessment will be conducted with Cochrane Collaboration's tool. Pairwise and network meta-analysis will be conducted using the WinBUGS V.1.4.3.37 and STATA V.13. Additionally, sensitivity analysis, subgroup analysis, quality assessment, Small-study effects and publication bias will be performed.
Ethics And Dissemination:
This work is based on published research and therefore does not require ethical approval. This review will be published in peer-reviewed journals.
Prospero Registration Number:
CRD42020188065.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies